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Abstract
Background: Adjunctive dexamethasone reduces mortality from tuberculous meningitis, but how it produces this effect is
not known. Matrix metalloproteinases (MMPs) are important in the immunopathology of many inflammatory CNS diseases
thus we hypothesized that that their secretion is important in TBM and might be influenced by dexamethasone.
Methodology/Principal Findings: The kinetics of cerebrospinal fluid (CSF) MMP and tissue inhibitors of MMPs (TIMPs)
concentrations were studied in a subset of HIV uninfected adults (n=37) with TBM recruited to a randomized, placebo-
controlled trial of adjuvant dexamethasone. Analysis followed a pre-defined plan. Dexamethasone significantly reduced CSF
MMP-9 concentrations in early follow up samples (median 5 days (range 3–8) of treatment), but had no significant influence
on other MMPs/TIMPs. Additionally CSF MMP-9 concentration was strongly correlated to concomitant CSF neutrophil count.
Conclusions/Significance: Dexamethasone decreased CSF MMP-9 concentrations early in treatment and this may represent
one mechanism by which corticosteroids improve outcome in TBM. The strong correlation between CSF MMP-9 and
neutrophil count suggests that polymorphonuclear leukocytes may play a central role in the early pathogenesis of TBM.
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Introduction
Tuberculous meningitis (TBM) is the most feared presentation
of extra-pulmonary tuberculosis (TB) because about a third of all
patients die from disease. We and others have previously shown
that adjunctive dexamethasone, administered with anti-tubercu-
losis drugs, improved the outcome of adults with TBM [1], but the
mechanism underlying this effect is not understood. Dexameth-
asone did not have any significant effect on cerebrospinal (CSF)
white cell infiltration or cytokine expression in 93 patients
recruited to the clinical trial [2]. A subset of patients had serial
brain magnetic resonance imaging, which suggested dexametha-
sone might decrease the incidence of hydrocephalus and infarction
[3]. In children steroids have been shown to reduce CSF protein
and cause a more rapid normalization in CSF glucose over
placebo [4]. However, no study has demonstrated the mechanism
by which dexamethasone reduced case-fatality from TBM.
We hypothesized that dexamethasone improved outcome from
TBM byaltering the intra-cerebral expression of MMPand the tissue
inhibitors of MMPs (TIMPs). MMPs are important mediators of
extracellular matrix degradation and are implicated not only in
inflammatory central nervous system (CNS) diseases such as multiple
sclerosis, HIV dementia and Alzheimer’s disease but also in TB
[5–7]. The blood brain barrier (BBB) is rich in type IV collagen, a
substrate of MMP-9 (gelatinase B), and its breakdown is a key initial
step in the pathophysiology of CNS leukocyte influx [8,9]. We and
others have shown that CSF concentrations of MMP-9 are elevated
in all forms of meningitis and CSF MMP-9 concentrations (corrected
forCSFwhite cellcount)were significantlyassociated with fatalTBM
and the extent of cerebral tissue damage [10,11]. We found that IFN-
c synergistically increases MMP-9 secretion from astrocytes, the most
abundant CNS cell and a key component of the BBB [12]. Mouse
models of pyogenic bacterial meningitis demonstrate MMP-9:TIMP-
1 ratios are important predictors of tissue destruction, although
MMP-9 may also have a significant role in host defense [13,14]. Our
cellular studies on TB-infected macrophages implicate MMP-1
(collagenase-1),-3(stromelysin-1),-7(matrilysin)and-10(stromelysin-
2) as critical in the host response to TB [15].
In this study, we measured serial CSF concentrations of a
number of MMPs/TIMPs identified as key in TB in a sub-set of
adults with TBM recruited to a randomized, placebo-controlled
trial of adjunctive dexamethasone [1]. Our aim was to investigate
the relationship between dexamethasone treatment, CSF MMP/
TIMP expression, and clinical outcome.
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Comparison of baseline variables
We havecompared thebaselineclinicalfeaturesofthoseincluded
in the MMP study (n=37) with the rest of the proven HIV
uninfectedpatientsrecruitedtothecontrolledtrial(n=400)(table1).
Comparison of the patients who received placebo or dexametha-
sone in the MMP study revealed only CSF opening pressure was
significantly different between the groups. The patients were well-
balanced with regard to the most important prognostic variables
(MRC grade and coma score). Comparison of the patients in the
MMPstudywiththerest ofthe HIVuninfected patients recruitedto
the trial revealed some important similarities and differences.
Clinical assessments of disease severity (by MRC grade and
Glasgow coma score) were not significantly different between the
two study groups. However, the patients not included in the MMP
study were significantly older and lighter, had lower numbers of
white cells in the CSF, and had worse outcomes (table 1).
185 CSF specimens were taken from the 37 patients included in
the MMP study. 141 (76%) specimens were available for analysis
of longitudinal changes in MMP/TIMP concentrations: 66/94
(70%) were from placebo and 75/91 (82%) from dexamethasone
group patients (a mean of 3.8 (+/21.2) samples per patient).
Baseline CSF MMP and TIMP concentrations
Baseline pre-treatment concentrations of MMPs and TIMPs are
summarized in table 2 and are similar between the two groups
with the exception of TIMP-2, which was significantly higher in
the patients give placebo. MMP-2, -3 and -9 concentrations were
detectable in all 30 pre-treatment CSF samples analyzed and
MMP-8 concentrations were detectable in 29 (97%). CSF
concentrations of MMP-1 and -7 were only detectable in 9
(30%) patients and MMP-10 in 10 (33%) patients. All 30 patients
had detectable TIMP-1 and -2 and 29 (97%) patients had
detectable CSF TIMP-4.
Dexamethasone specifically reduces CSF MMP-9
concentration at day 5 of TBM treatment
22 patients had both a pre-treatment and at least one paired
‘early’ follow up sample available for analysis, taken a median 5
Table 1. Comparison of the baseline clinical features from patients in the study of MMPs with all other HIV uninfected patients
recruited to the controlled trial of dexamethasone.
MMP study sub-group MMP study sub-group
All other HIV uninfected patients
in dexamethasone trial P-value b
Variable
a Placebo Dexamethasone
Number (n) 19 18 400
Age (yrs) 31 (23.0–44.0) 25 (19.3–40.5) 40 (29–58) 0.001
Gender (M:F) n 7:12 8:10 13:10 0.098
TBM grade n (%)
I 2 (10.5) 6 (33.3) 142 (35.5)
II 11 (57.9) 7 (38.9) 180 (45.0) 0.224
III 6 (31.6) 5 (27.8) 78 (19.5)
Weight mean (sd–kg) 49.3 (8.5) 48.4 (6.5) 45.0 (40.0–50.0) 0.004
Temperature
oC 38.7 (38.0–39.3) 39.0 (38.0–39.5) 38.0 (37.5–39.0) 0.001
GCS at presentation 13 (10–14) 13.5 (10–15) 14 (12–15) 0.210
Duration of symptoms (days) 17 (12–21) 17 (12–26.25) 15 (10–30) 0.617
Cranial Nerve Palsy n (%) 8 (42.1) 6 (33.3) 115 (28.8) 0.353
Hemiparesis n (%) 2 (10.5) 3 (16.7) 59 (14.8) 0.552
Paraparesis n (%) 0 (0) 1 (5.6) 33 (8.3) 0.241
Opening pressure (cm)
c 18 (16–32) 33 (19–39) 22 (13–39) 0.478
Total WCC (cells/ml) 470 (130–625) 250 (147–613) 104 (27–251) ,0.001
Neutrophils (%) 30 (18–43) 40 (24.5–67.5) 5 (0–20.0) ,0.001
Lymphocytes (%) 70 (57–82) 60 (42–75.5) 95 (80.0–100) ,0.001
Protein (g/L) 1.6 (1.0–3.0) 2.0 (1.5–3.0) 1.4 (0.8–2.2) 0.020
Lactate (mmol/L) 6.2 (4.6–8.1) 6.6 (5.2–8.9) 5.1 (3.6–6.9) 0.024
Glucose ratio–CSF/blood 0.17 (0.09–0.30) 0.25 (0.14–0.34) 0.29 (0.19–0.39) 0.004
Albumin ratio–CSF/blood (%) 1.12 (0.58–2.84) 2.03 (0.65–2.73) NA
d NA
d
Death n (%) 3 (15.8) 2 (11.1) 120 (30.0) 0.016
Combined poor outcome n (%) 4 (21.1) 4 (22.2) 171 (42.8) 0.006
aValues are median (IQR) or number (percentage) unless stated otherwise.
bComparison between the variables of patients in the MMP study with all other patients recruited to the controlled trial (continuous variables compared by the Mann-
Whitney U test; categorical variables by the Chi square test).
cComparison of baseline variables between patients given placebo or dexamethasone in the MMP study showed only CSF opening pressure was significantly different
(P,0.05) between the groups.
dData not available in this group.
doi:10.1371/journal.pone.0007277.t001
MMPs in TBM
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between placebo and dexamethasone groups. Only CSF MMP-9
concentrations were significantly lower in the early follow-up
samples of patients given dexamethasone compared to placebo
(p=0.01, figure 1), confirmed by repeated measures ANOVA with
CSF white cell count as a covariate (p=0.002). 3/11 (27%)
patients in the placebo group had a fall in their CSF MMP-9
concentration compared with 9/11 (82%) of the dexamethasone
group between pre-treatment and the early follow-up sample
(p=0.03). However, we could not find a significant relationship
between those patients whose CSF MMP-9 concentration fell and
outcome; 1/12 (8%) patients with a fall in CSF MMP-9 died and
1/10 (10%) died in the non-faller group, the data were similar for
death or disability (data not shown). There was a similar but less
marked effect of dexamethasone on MMP-8 concentrations. A
trend for lower CSF MMP-8 concentrations in the dexamethasone
arm (p=0.08) was not significant in the repeated measures
ANOVA. TIMPs are the natural inhibitors of MMPs but we were
unable to find any effect of dexamethasone on changes in CSF
TIMP concentration in the same early follow-up (day 5) samples
(figure 2).
MMP-9 concentrations at later time points were not statistically
different between the two groups. At day 30 CSF MMP-9
concentration was 252.6 ng/ml (IQR 154.6–298.6) in the placebo
group and 249.9 ng/ml (IQR 67.5–406.6) in the dexamethasone
group. At day 60 CSF MMP-9 concentration was 281.6 ng/ml
(IQR 94.1–345.0) in the placebo group and 181.9 ng/ml (IQR
101.8–300.7) in the dexamethasone group. Day 270 concentra-
tions for all CSF MMP/TIMP and their statistical change from
baseline are summarized in table 3. Of note MMP-3, -8, -9 and
TIMP-1 fell and TIMP-4 rose significantly over the course of 9
months anti-tuberculosis treatment. No other significant relation-
ships were found at any time points for any other MMPs and
treatment group. MMP/TIMP concentrations at all time points
for both groups have been summarized in supplementary table S1.
The relationship between CSF WCC and MMP-9
concentrations
Neutrophils play a key but possibly under-recognized role in
host defense to mycobacteria and release preformed MMP-9 from
granzymes to cross the BBB [16,17]. CSF MMP-9 concentration
and neutrophil count were strongly correlated on analysis of all
141 samples (R
2=0.19, p,0.001). There was a significant
correlation between MMP-9 concentration and CSF WCC
(R
2=0.31, P=0.004) in all 29 available early follow-up (day 5)
samples and a stronger correlation with CSF neutrophil count
(Figure 3, R
2=0.52, p,0.001) which was dexamethasone
independent. CSF neutrophil count was not independently related
to outcome.
The relationship between MMP-9 and other CSF
inflammatory parameters
BBB disruption is potentially related to MMP activity [18].
There were significant correlations between CSF total protein (the
only CSF analyte to fall significantly due to dexamethasone [2])
and MMP-9 (R
2=0.18, p,0.001) concentrations but we could
find no relationship between the albumin index (a marker of BBB
permeability) and CSF MMP/TIMP concentration. At the day 5
time point MMP-8 and -9 were closely correlated (R
2=0.67,
p,0.001, n=29) but there was only a weak relationship between
MMP-9 and its specific inhibitor TIMP-1 (R
2=0.13, p,0.05,
n=29). There were no other relationships between MMP-9 and
any of the other MMP/TIMP concentrations at this time point.
We investigated the relationship between CSF concentrations of
TNF-a, IFN-c, IL-6, IL-8, IL-10 (data not presented) and MMP-9
in all 141 specimens and found only IL-10 and MMP-9 to be
correlated (R
2=0.22, p,0.001). Concentrations of IL-1b and IL-
12p70 levels were below the level of detection in all but 6 and 8
specimens respectively so were not analyzed. Specific examination
of pre-treatment and early follow-up samples did not reveal any
other significant relationships.
Analysis of all baseline clinical and laboratory variables
and relationship to baseline clinical severity and
treatment outcome measurements
We investigated the relationship between increasing severity of
coma (i.e. GCS of ,15 or not on admission to hospital) and
clinical and laboratory variables including CSF MMP/TIMP
concentrations by logistic regression. In univariate analysis only
gender and CSF chloride concentration went forward to entry into
the final model, but neither remained significant.
We then performed univariate analysis to look for relationships
between combined poor outcome (death and disability) and
clinical and laboratory findings. Gender, baseline GCS, cranial
nerve palsy and hemiparesis on presentation went forward into
multivariate analysis where only hemiparesis remained significant
in the final model (OR=0.05, p=0.04 [95% CI 0.003, 0.92]).
We found no other significant relationships between pre-
treatment MMP/TIMP concentrations (n=30) and mortality,
cranial nerve palsy, hemiparesis and paraparesis on admission by
multivariate analysis, although there was a significant relationship
between lower pre-treatment MMP-2 concentrations in CSF and
hemiparesis (OR=0, p=0.02 [95% CI 0, 0.24]) on univariate
analysis. There was no relationship between duration of symptoms
and MMP/TIMP concentrations.
Discussion
In this study we have investigated the influence of dexameth-
asone on the CSF secretion of MMPs/TIMPs in (n=37) adults
with TBM. Despite the small number of patients we found
dexamethasone significantly decreased CSF MMP-9 concentra-
tions early in the course of TBM treatment and thus may represent
one mechanism by which corticosteroids improve outcome. As
dexamethasone did not influence the CSF concentrations of other
MMPs this suggests a specific mode of action. Our previous
Table 2. Baseline CSF MMP/TIMP concentrations.
Variable* Placebo Dexamethasone
Number (n) 15 15
MMP-1 (ng/ml) 0.13 (0.13–0.49) 0.13 (0.13–0.24)
MMP-2 (ng/ml) 47.0 (37.5–53.2) 42.2 (33.3–48.7)
MMP-3 (ng/ml) 1.22 (0.80–1.46) 0.97 (0.27–1.66)
MMP-7 (ng/ml) 0.078 (0.078–0.079) 0.078 (0.075–0.12)
MMP-8 (ng/ml) 18.9 (10.9–28.4) 12.6 (7.9–28.6)
MMP-9 (ng/ml) 108.3 (37.8–226.5) 110.8 (93.4–269.2)
MMP-10 (ng/ml) 0.04 (0.04–0.11) 0.04 (0.04–0.11)
TIMP-1 (ng/ml) 248.6 (116.2–421.1) 180.1 (83.9–241.0)
TIMP-2 (ng/ml)
# 31.6 (28.2–38.6) 23.0 (20.9–29.6)
TIMP-4 (ng/ml) 0.43 (0.32–0.47) 0.49 (0.32–0.87)
*Values are median (IQR) unless stated otherwise.
#p=0.01 for group comparison.
doi:10.1371/journal.pone.0007277.t002
MMPs in TBM
PLoS ONE | www.plosone.org 3 September 2009 | Volume 4 | Issue 9 | e7277Figure 1. Dexamethasone reduces CSF MMP-9 concentrations in early follow up samples. Paired CSF samples from patients with
tuberculous meningitis were taken pre-treatment and at early follow up, a median 5 days (range 3–8) into anti-tuberculosis therapy, and analyzed for
MMP-1, -2, -3, -7, -8, -9& -10 concentration by ELISA(MMP-6, -7 & -8do not exist). Patientswhoreceived placebo (lightgreybars, n=11) hadsignificantly
higherMMP-9concentrations intheirearlyfollow-upCSFsamples thanthosewhoreceiveddexamethasone(darkgreybars, n=11).*, p=0.01.Theblack
line represents the median value and the box the interquartile range. Whiskers represent 1.5 times the interquartile range away from the box.
doi:10.1371/journal.pone.0007277.g001
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dexamethasone on serial CSF cytokines or chemokines, although
CSF protein fell faster in the dexamethasone treated group and
there was a trend toward lower IFN-c concentrations [2]. These
data are consistent with our in vitro data that indicate IFN-c
influences intra-cerebral MMP-9 secretion[12].
MMP-9 is quantitatively the most significant MMP released by
macrophages and concentrations are increased in lungs and
Figure 2. CSF TIMP concentrations in early follow up samples are
not affected by dexamethasone. Paired CSF samples from patients
with tuberculous meningitis were taken pre-treatment and at early follow
up, a median 5 days (range 3–8) into anti-tuberculosis therapy, and
analyzed for TIMP-1, -2, & -4 concentrations by ELISA. The black line
represents the median value and the box the interquartile range. Whiskers
represent 1.5 times the interquartile range away from the box.
doi:10.1371/journal.pone.0007277.g002
Table 3. Day 270 CSF MMP/TIMP concentrations (n=19).
Variable CSF Concentration [median (IQR)]* P value
#
MMP-1 (ng/ml) 0.13 (0.13–0.13) 0.34
MMP-2 (ng/ml) 36.7 (33.0–50.7) 0.26
MMP-3 (ng/ml) 0.26 (0.12–0.45) ,0.001
MMP-7 (ng/ml) 0.08 (0.07–0.11) 0.63
MMP-8 (ng/ml) 0.03 (0.03–0.03) ,0.001
MMP-9 (ng/ml) 4.7 (0.9–12.2) ,0.001
MMP-10 (ng/ml) 0.04 (0.04–0.05) 0.20
TIMP-1 (ng/ml) 23.9 (15.2–36.0) ,0.001
TIMP-2 (ng/ml) 26.4 (23.1–37.4) 0.82
TIMP-4 (ng/ml) 2.1 (1.4–3.1) ,0.001
*Data are presented unstratified for treatment group.
#Comparison to baseline value in table 2.
doi:10.1371/journal.pone.0007277.t003
Figure 3. CSF MMP-9 concentration and CSF neutrophil count
are significantly correlated in early follow up samples. Early
follow-up CSF samples, taken a median of 5 days (range 3–8, n=29)
into anti-tuberculosis treatment, from patients with tuberculous
meningitis were analyzed for correlation between absolute neutrophil
count and MMP-9 concentration (measured by ELISA). The R
2 value for
the correlation was 0.52 (p,0.001). Patients who received placebo are
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may be raised and associated with pulmonary disease severity [21].
In vitro, MMP-9 is secreted from monocyte cell lines in response to
stimulation by a number of TB components such as lipoarabino-
mannan (LAM), a process dependent upon the transcription factor
AP-1 [19,22]. Previous studies suggest MMP-9 may be an
important molecule in TBM pathogenesis. A study of adults with
TBM, viral, and bacterial meningitis found increased CSF MMP-
9 concentrations were associated with more severe disease and
death in all cases [11]. A study of TBM alone has replicated this
finding [10]. Other cellular work demonstrates that M.tb-infected
monocytes drive a network involving IFN-c, TNF-a, IL-1b and
NFkB resulting in increased astrocyte MMP-9 secretion without
altered TIMP-1/2 secretion indicating a role for glial cells in the
development of the matrix degrading phenotype present in CNS
TB [12,23]. However, murine studies suggest MMP-9 is also
important in host defense to M. tuberculosis. Macrophages from
mice resistant to M. tuberculosis produce more MMP-9 mRNA in
response to intracellular infection than susceptible mice [24]. Non-
specific MMP inhibition blocked early dissemination of M.
tuberculosis and MMP-9-knockout mice had reduced pulmonary
recruitment of macrophages and poorer granuloma formation
[25]. Therefore in vivo a balance may exist between the MMP-9
necessary for host-defense and excess causing the unwanted effects
opposed by dexamethasone.
Our data suggest that the majority of early CSF MMP-9 is
released from neutrophils as there was a strong correlation
between both baseline values. Other studies have reported strong
correlations between MMP-9 and neutrophils in viral meningitis
and with total white cells in TBM [26,27]. Neutrophils release
large amounts of preformed MMP-9 in response to many
inflammatory stimuli, which may explain the lack of correlation
observed between CSF MMP-9 and the pro-inflammatory
cytokines measured [28]. Additionally there was a trend in our
data to suggest that MMP-8, a collagenase principally derived
from neutrophils and important in bacterial meningitis, might also
be decreased by dexamethasone [16,29]. The role of the
neutrophil in the pathogenesis of TB is not well understood.
Peripheral neutrophil counts have been inversely related to risk of
TB in contacts of infectious cases and neutrophil depletion ex vivo
impaired the ability of whole blood to restrict mycobacterial
growth via depletion of secreted anti-microbial peptides [17]. A
report that neutrophil derived anti-microbial peptides are released
in response to M. tuberculosis infection but not expressed in the
tuberculous granuloma is consistent with the proposed early role
for neutrophils in TB [22]. In addition, adults with TBM and a
high proportion of neutrophils in the CSF have an increased
chance of survival [30].
Given the strong correlation between CSF neutrophils and
MMP-9 concentrations we investigated the influence of dexa-
methasone on CSF neutrophil numbers, but did not observe any
differences between the treatment groups at any time point.
However, dexamethasone may affect function rather than absolute
numbers. Corticosteroids can rapidly prevent neutrophil degran-
ulation independently of effects on protein synthesis [31]. The
restricted release of neutrophil-derived proteins in dexamethasone
treated patients may have contributed to the significant reduction
in CSF protein observed in the dexamethasone group in the
published study involving a larger number of patients from the
parent trial [2].
The study has a number of limitations. First, we only studied a
small sub-group of patients recruited to the controlled trial. In
addition we only studied time points at 0 and 5 days that lead to
our conclusions, further work must delineate more clearly when
dexamethasone is having this early effect. We could only study
patients from one centre, with bacteriologically confirmed disease,
in whom multiple serial CSF specimens were available. Therefore
because of its small size the study lacked power to detect small
effects of dexamethasone and to link effects with outcome. In
addition, the patients selected may not be representative of all the
patients in the trial. However, the baseline clinical variables most
strongly associated with outcome – disease severity grade and
coma score - were well matched, both within the patients included
in the MMP study and when these patients were compared with
the rest of the trial patients. The worse outcomes in patients not
included in the MMP study may be partly explained by their older
age and lower numbers of white cells in the CSF, both
independent risk factors for death from TBM [1]. Also, we used
ELISAs that detected both active and pro-MMP-9 and thus could
not differentiate between biologically active and inactive or
degraded MMP-9 [32]. Differences in the activity of MMP-9
(assessed by zymography) have been reported in experimental
pyogenic meningitis where treatment with antibiotics alone
increased CSF MMP-9 activity, but dexamethasone co-adminis-
tration suppressed this effect [33].
In summary, this investigation has shown that dexamethasone
may influence outcome from TBM by reducing MMP-9 secretion.
However, future research needs to delineate the roles of
neutrophils and their MMPs, specifically MMP-8 and -9, in the
early stages of TBM treatment more clearly. Targeting neutrophil-
derived, MMP-driven, inflammatory responses early in TBM may
be a potential therapeutic strategy.
Methods
Study participants and setting
We studied a subset of patients from a previously reported
randomized, double-blind, placebo-controlled trial of adjunctive
dexamethasone for the treatment of TBM in 545 Vietnamese
adults [1]. To be eligible for selection for the current study patients
had to have been recruited at the Hospital for Tropical Diseases
(HTD), Ho Chi Minh City, have a microbiologically confirmed
diagnosis of TBM (Mycobacterium tuberculosis cultured from the
CSF), negative HIV-1 & 2 antibodies, and at least two serial CSF
specimens taken within the first 60 days of treatment (when
dexamethasone was stopped) available for analysis, unless they had
died within this period.
Disease severity at admission was defined by the Glasgow coma
scale (GCS). Assessment of GCS was performed by summation of
clinical assessment of eye opening (awarded 1–4 points), best
verbal response (1–5 points) and best motor function (1–6 points)
where lower values indicate more severe neurological dysfunction
[34]. Disease severity was also assessed using the United Kingdom
Medical Research Council grade (UK MRC) for TBM [34]:
patients in grade I had a GCS of 15 (fully conscious) and no focal
neurological signs; patients in grade II had a GCS of between 11
and 14 and/or focal neurological signs; and patients in grade III
had severe coma with a GCS of less than 11.
The ethical and scientific committees of Imperial College,
Oxford University and the Hospital for Tropical Diseases
approved the study and written, informed consent to participate
in the study was obtained from the patients or their relatives. All
clinical investigation was conducted according to the principles
expressed in the Declaration of Helsinki.
Treatment and specimen collection
Adults were allocated randomly to start dexamethasone sodium
phosphate or placebo as soon as possible after the start of four drug
MMPs in TBM
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adults with grade II or III disease received intra-venous study drug
for 4 weeks (week 1 0.4 mg/kg/day); week 2 0.3 mg/kg/day, week
3 0.2 mg/kg/day, week 4 0.1 mg/kg/day), then 4 weeks of tablets
starting at 4 mg total dose per day, reducing by 1 mg per week
until zero. Those with grade I disease received 2 weeks of intra-
venous study drug (week 1 0.3 mg/kg/day, week 2 0.2 mg/kg/
day) then 4 weeks of tablets (week 3 0.1 mg/kg/day; then 3 mg
total per day reducing by 1 mg per week until zero). Serial CSF
samples (frozen at 270uC) and routine clinical investigations were
collected as part of normal clinical care pre-treatment and on
study days 3, 7, 30, 60 and 270.
Assessment of the clinical and CSF inflammatory
response to treatment
The primary outcome of the trial was death or severe disability
9 months after randomization and was assessed blind to the
treatment allocation [1]. Likewise, treatment allocation was
unknown to those assessing conventional and experimental CSF
inflammatory responses including MMPs/TIMPs. CSF white cell
count, protein, glucose and lactate concentrations were deter-
mined by standard methods. Blood brain barrier integrity was
assessed by measurement of paired CSF and plasma albumin
concentrations by standard methods. The albumin index was
calculated using the formula [albumincsf]/[albuminplasma] [30]. The
concentrations of CSF cytokines (IFN-c, TNF-a, and the
interleukins -1b, -6, -8, -10, and 12p70) were determined by
cytometric bead array assay (BD Biosciences) as described [2].
CSF MMP and TIMP concentration measurement
MMP-1, -2, -3, -7, -8, -9 and -10 and TIMP-1, -2 and -4 were
measured by ELISA (R&D, Abingdon, UK) according to the
manufacturer’s instructions. The lower level of sensitivity for the
ELISAs were 156 pg/ml for MMP-1 and -7, 78 pg/ml for MMP-
2 and -10, and 31 pg/ml for MMP-3, -8, -9, TIMP-1, -2 and -4.
Samples with high MMP/TIMP concentrations were diluted as
appropriate. Values below the level of detection were assigned an
arbitrary value halfway between 0 and the lower level of
sensitivity.
Statistical analysis
The analysis followed a pre-defined plan, unless otherwise stated
as exploratory analysis. Continuous variables were compared by
Student’s t-test if normally distributed and Mann-Whitney U test if
non-normally distributed. Where more than two groups were
compared the Kruskal-Wallis test was used for non-parametric
data. Categorical data were compared using Fisher’s exact test or
the X
2 test. All p-values were two sided and a value of ,0.05 was
taken as significant. The changes in MMP/TIMP concentration
between pre-treatment and follow-up samples were calculated
using repeated measures ANOVA with dexamethasone as a
covariate. Baseline MMPs and TIMPs were analyzed by
univariate analysis to examine relationships between presenting
clinical features and the specific outcomes of death and combined
poor outcome (defined in the original trial as death or severe
disability at 9 month follow-up). Clinical and laboratory features
with P,0.15 were then entered into a multivariate model using
forward and backward likelihood ratio logistic regression. All
analyses were performed using SPSS version 15.0 (SPSS Corp,
Chicago, IL, US).
Supporting Information
Table S1 Summary of CSF MMP/TIMP concentrations at all
time points. # Data for all patients presented, paired analysis
presented in text.
Found at: doi:10.1371/journal.pone.0007277.s001 (0.05 MB
DOC)
Acknowledgments
The authors wish to thank the doctors and nurses at The Hospital for
Tropical Diseases who cared for the patients and allowed collection of
samples for this study to occur.
Author Contributions
Conceived and designed the experiments: JAG JF JSF GET. Performed the
experiments: JAG CTHT. Analyzed the data: JAG GET. Contributed
reagents/materials/analysis tools: MTHN PHN SXD NDTH CVL HTT.
Wrote the paper: JAG CTHT JF HTT JSF GET. Recruited patients to the
original trial: CTHT MTHN PHN SXD NDTH CVL HTT. Collected
samples for the original trial: MTHN PHN SXD NDTH CVL HTT.
References
1. Thwaites GE, Nguyen DB, Nguyen HD, Hoang TQ, Do TT, et al. (2004)
Dexamethasone for the treatment of tuberculous meningitis in adolescents and
adults. N Engl J Med 351: 1741–1751.
2. Simmons CP, Thwaites GE, Quyen NT, Chau TT, Mai PP, et al. (2005) The
clinical benefit of adjunctive dexamethasone in tuberculous meningitis is not
associated with measurable attenuation of peripheral or local immune responses.
J Immunol 175: 579–590.
3. Thwaites GE, Macmullen-Price J, Tran TH, Pham PM, Nguyen TD, et al.
(2007) Serial MRI to determine the effect of dexamethasone on the cerebral
pathology of tuberculous meningitis: an observational study. Lancet Neurol 6:
230–236.
4. Schoeman JF, Elshof JW, Laubscher JA, Janse van Rensburg A, Donald PR
(2001) The effect of adjuvant steroid treatment on serial cerebrospinal fluid
changes in tuberculous meningitis. Ann Trop Paediatr 21: 299–305.
5. McGeer PL, McGeer EG (1999) Inflammation of the brain in Alzheimer’s
disease: implications for therapy. J Leukoc Biol 65: 409–415.
6. Rosenberg GA (2005) Matrix metalloproteinases biomarkers in multiple
sclerosis. Lancet 365: 1291–1293.
7. Zhang K, McQuibban GA, Silva C, Butler GS, Johnston JB, et al. (2003) HIV-
induced metalloproteinase processing of the chemokine stromal cell derived
factor-1 causes neurodegeneration. Nat Neurosci 6: 1064–1071.
8. Okada S, Kita H, George TJ, Gleich GJ, Leiferman KM (1997) Migration of
eosinophils through basement membrane components in vitro: role of matrix
metalloproteinase-9. Am J Respir Cell Mol Biol 17: 519–528.
9. van Horssen J, Bo L, Vos CM, Virtanen I, de Vries HE (2005) Basement
membrane proteins in multiple sclerosis-associated inflammatory cuffs: potential
role in influx and transport of leukocytes. J Neuropathol Exp Neurol 64: 722–729.
10. Matsuura E, Umehara F, Hashiguchi T, Fujimoto N, Okada Y, et al. (2000)
Marked increase of matrix metalloproteinase 9 in cerebrospinal fluid of patients
with fungal or tuberculous meningoencephalitis. J Neurol Sci 173: 45–52.
11. Price NM, Farrar J, Tran TT, Nguyen TH, Tran TH, et al. (2001) Identification
of a matrix-degrading phenotype in human tuberculosis in vitro and in vivo.
J Immunol 166: 4223–4230.
12. Harris JE, Fernandez-Vilaseca M, Elkington PT, Horncastle DE, Graeber MB,
et al. (2007) IFNgamma synergizes with IL-1beta to up-regulate MMP-9
secretion in a cellular model of central nervous system tuberculosis. FASEB J 21:
356–365.
13. Bottcher T, Spreer A, Azeh I, Nau R, Gerber J (2003) Matrix metalloproteinase-
9 deficiency impairs host defense mechanisms against Streptococcus pneumo-
niae in a mouse model of bacterial meningitis. Neurosci Lett 338: 201–204.
14. Sellner J, Leib SL (2006) In bacterial meningitis cortical brain damage is
associated with changes in parenchymal MMP-9/TIMP-1 ratio and increased
collagen type IV degradation. Neurobiol Dis 21: 647–656.
15. Elkington PT, Nuttall RK, Boyle JJ, O’Kane CM, Horncastle DE, et al. (2005)
Mycobacterium tuberculosis but not vaccine BCG specifically up-regulates
matrix metalloproteinase-1. Am J Respir Crit Care Med 172: 1596–1604.
16. Cuadrado E, Ortega L, Hernandez-Guillamon M, Penalba A, Fernandez-
Cadenas I, et al. (2008) Tissue plasminogen activator (t-PA) promotes neutrophil
degranulation and MMP-9 release. J Leukoc Biol 84: 207–214.
17. Martineau AR, Newton SM, Wilkinson KA, Kampmann B, Hall BM, et al.
(2007) Neutrophil-mediated innate immune resistance to mycobacteria. J Clin
Invest 117: 1988–1994.
18. Rosenberg GA (2002) Matrix metalloproteinases in neuroinflammation. Glia 39:
279–291.
MMPs in TBM
PLoS ONE | www.plosone.org 7 September 2009 | Volume 4 | Issue 9 | e727719. Chang JC, Wysocki A, Tchou-Wong KM, Moskowitz N, Zhang Y, et al. (1996)
Effect of Mycobacterium tuberculosis and its components on macrophages and
the release of matrix metalloproteinases. Thorax 51: 306–311.
20. Hoheisel G, Sack U, Hui DS, Huse K, Chan KS, et al. (2001) Occurrence of
matrix metalloproteinases and tissue inhibitors of metalloproteinases in
tuberculous pleuritis. Tuberculosis (Edinb) 81: 203–209.
21. Hrabec E, Strek M, Zieba M, Kwiatkowska S, Hrabec Z (2002) Circulation level
of matrix metalloproteinase-9 is correlated with disease severity in tuberculosis
patients. Int J Tuberc Lung Dis 6: 713–719.
22. Rivera-Marrero CA, Schuyler W, Roser S, Roman J (2000) Induction of MMP-
9 mediated gelatinolytic activity in human monocytic cells by cell wall
components of Mycobacterium tuberculosis. Microb Pathog 29: 231–244.
23. Harris JE, Nuttall RK, Elkington PT, Green JA, Horncastle DE, et al. (2007)
Monocyte-astrocyte networks regulate matrix metalloproteinase gene expression
and secretion in central nervous system tuberculosis in vitro and in vivo.
J Immunol 178: 1199–1207.
24. Keller C, Lauber J, Blumenthal A, Buer J, Ehlers S (2004) Resistance and
susceptibility to tuberculosis analysed at the transcriptome level: lessons from
mouse macrophages. Tuberculosis (Edinb) 84: 144–158.
25. Taylor JL, Hattle JM, Dreitz SA, Troudt JM, Izzo LS, et al. (2006) A role for
matrix metalloproteinase-9 in granuloma formation during pulmonary Myco-
bacterium tuberculosis infection. Infect Immun 74: 6135–6144.
26. Lee KY, Kim EH, Yang WS, Ryu H, Cho SN, et al. (2004) Persistent increase of
matrix metalloproteinases in cerebrospinal fluid of tuberculous meningitis.
J Neurol Sci 220: 73–78.
27. Sulik A, Wojtkowska M, Oldak E (2008) Elevated Levels of MMP-9 and TIMP-
1 in the Cerebrospinal Fluid of Children with Echovirus Type 30 and Mumps
Meningitis. Scand J Immunol 68: 323–327.
28. Opdenakker G, Van den Steen PE, Dubois B, Nelissen I, Van Coillie E, et al.
(2001) Gelatinase B functions as regulator and effector in leukocyte biology.
J Leukoc Biol 69: 851–859.
29. Leppert D, Leib SL, Grygar C, Miller KM, Schaad UB, et al. (2000) Matrix
metalloproteinase (MMP)-8 and MMP-9 in cerebrospinal fluid during bacterial
meningitis: association with blood-brain barrier damage and neurological
sequelae. Clin Infect Dis 31: 80–84.
30. Thwaites GE, Simmons CP, Than Ha Quyen N, Thi Hong Chau T, Phuong
Mai P, et al. (2003) Pathophysiology and prognosis in vietnamese adults with
tuberculous meningitis. J Infect Dis 188: 1105–1115.
31. Liu L, Wang YX, Zhou J, Long F, Sun HW, et al. (2005) Rapid non-genomic
inhibitory effects of glucocorticoids on human neutrophil degranulation.
Inflamm Res 54: 37–41.
32. Snoek-van Beurden PA, Von den Hoff JW (2005) Zymographic techniques for
the analysis of matrix metalloproteinases and their inhibitors. Biotechniques 38:
73–83.
33. Liu X, Han Q, Sun R, Li Z (2008) Dexamethasone regulation of matrix
metalloproteinase expression in experimental pneumococcal meningitis. Brain
Res 1207: 237–243.
34. Teasdale G, Jennett B (1974) Assessment of coma and impaired consciousness. A
practical scale. Lancet 2: 81–84.
MMPs in TBM
PLoS ONE | www.plosone.org 8 September 2009 | Volume 4 | Issue 9 | e7277